Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6261246rdf:typepubmed:Citationlld:pubmed
pubmed-article:6261246lifeskim:mentionsumls-concept:C0521428lld:lifeskim
pubmed-article:6261246lifeskim:mentionsumls-concept:C0001655lld:lifeskim
pubmed-article:6261246lifeskim:mentionsumls-concept:C0031676lld:lifeskim
pubmed-article:6261246lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6261246lifeskim:mentionsumls-concept:C0597513lld:lifeskim
pubmed-article:6261246lifeskim:mentionsumls-concept:C1879746lld:lifeskim
pubmed-article:6261246lifeskim:mentionsumls-concept:C1547011lld:lifeskim
pubmed-article:6261246lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:6261246pubmed:issue12lld:pubmed
pubmed-article:6261246pubmed:dateCreated1981-6-13lld:pubmed
pubmed-article:6261246pubmed:abstractTextIntraperitoneal injection of maximally effective doses of corticotropin(1-24) [ACTH(1-24)] provoked maximal increases in rat adrenal phospholipids as follows: phosphatidic acid within 1.5-2 min, phosphatidylinositol and phosphatidylglycerol within 4-6 min, and polyphosphoinositides and corticosterone within 5-15 min. Continued maximal adrenal stimulation by ACTH(1-18) treatment caused sustained increases in adrenal phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, polyphosphoinositides, and corticosterone. Treatment with cycloheximide during this steady-state caused rapid decreases in all of these substances to basal levels. The observed half-lives of adrenal phosphatide acid, phosphatidylinositol, polyphosphoinositides, phosphatidylglycerol, and corticosterone during cycloheximide inhibition were 0.15, 1.0, 1.7, 3.3, and 3.5 min, respectively. Calculated production rates during maximal ACTH stimulation were 1060, 991, 90, 34, and 41 nmol/g of tissue per min, respectively. These findings suggest that (i) an initial effect of ACTH on de novo synthesis of phosphatidic acid can account for all subsequently observed increases in other phospholipid derivatives of CDP-diacylglycerol, (ii) a labile protein is required for the ACTH-induced increase in phosphatidic acid, (iii) the phosphatidate leads to polyphosphoinositide-polyglycerophospholipid pathway is rapidly and dramatically responsive to hormonal stimulation, (iv) changes in steroidogenesis correlate well with changes in this phospholipid pathway, and (v) stimulation of this pathway is rapidly reversible.lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:languageenglld:pubmed
pubmed-article:6261246pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:citationSubsetIMlld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6261246pubmed:statusMEDLINElld:pubmed
pubmed-article:6261246pubmed:monthDeclld:pubmed
pubmed-article:6261246pubmed:issn0027-8424lld:pubmed
pubmed-article:6261246pubmed:authorpubmed-author:LarsonR ERElld:pubmed
pubmed-article:6261246pubmed:authorpubmed-author:FareseR VRVlld:pubmed
pubmed-article:6261246pubmed:authorpubmed-author:SabirM AMAlld:pubmed
pubmed-article:6261246pubmed:issnTypePrintlld:pubmed
pubmed-article:6261246pubmed:volume77lld:pubmed
pubmed-article:6261246pubmed:ownerNLMlld:pubmed
pubmed-article:6261246pubmed:authorsCompleteYlld:pubmed
pubmed-article:6261246pubmed:pagination7189-93lld:pubmed
pubmed-article:6261246pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:meshHeadingpubmed-meshheading:6261246-...lld:pubmed
pubmed-article:6261246pubmed:year1980lld:pubmed
pubmed-article:6261246pubmed:articleTitleKinetic aspects of cycloheximide-induced reversal of adrenocorticotropin effects on steroidogenesis and adrenal phospholipids in vivo.lld:pubmed
pubmed-article:6261246pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6261246lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6261246lld:pubmed